About Profluent Bio
Profluent Bio is a company based in Berkeley (United States) founded in 2022 by Alexander Meeske and Ali Madani. Profluent Bio has raised $150 million across 3 funding rounds from investors including Spark Capital, Insight Partners and Air Street Capital. Profluent Bio offers products and services including OpenCRISPR and ProGen3. Profluent Bio operates in a competitive market with competitors including Nimbus Therapeutics, Cradle, EvolutionaryScale, Evozyne and Frontier Medicines, among others.
- Headquarter Berkeley, United States
- Founders Alexander Meeske, Ali Madani
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Profluent Bio Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$150 M (USD)
in 3 rounds
-
Latest Funding Round
$106 M (USD), Series B
Nov 19, 2025
-
Investors
Spark Capital
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Profluent Bio
Profluent Bio offers a comprehensive portfolio of products and services, including OpenCRISPR and ProGen3.
AI-designed editor for gene modification in biological applications
System for authoring proteins in medicine and agriculture
People of Profluent Bio
Unlock access to complete
Funding Insights of Profluent Bio
Profluent Bio has successfully raised a total of $150M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $106 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Profluent Bio
Profluent Bio has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include Spark Capital, Insight Partners and Air Street Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Spark Capital is engaged in venture capital investments.
|
Locked | Locked | Locked | |
|
Investment firm scaling software and technology companies from early to late stages.
|
Locked | Locked | Locked | |
|
Venture capital firm investing in AI & life science sectors
|
Locked | Locked | Locked |
Investor details for Profluent Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Profluent Bio
Investment portfolio details for Profluent Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Profluent Bio
Detailed financials for Profluent Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Profluent Bio Comparisons
Peer comparison for Profluent Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Profluent Bio
Profluent Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nimbus Therapeutics, Cradle, EvolutionaryScale, Evozyne and Frontier Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Chemoproteomics solutions are provided for protein design and development.
|
|
| Locked | Locked | Locked |
Provider of an AI models for protein design
|
|
| Locked | Locked | Locked |
Developer of proteins using protein engineering technology
|
|
| Locked | Locked | Locked |
Bioinformatics platform is developed for drug discovery and chemoproteomics.
|
Detailed competitors of Profluent Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Profluent Bio
Complete news archive for Profluent Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Profluent Bio
Profluent Bio was founded in 2022 and raised its 1st funding round 1 year after it was founded.
Profluent Bio is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Ali Madani is the current CEO of Profluent Bio. They have also founded this company.
Profluent Bio is a funded company, having raised a total of $150M across 3 funding rounds to date.
Profluent Bio was founded in 2022 in Berkeley, United States. An artificial intelligence platform for protein design is offered within the biotechnology sector. Deep generative models are employed to create novel proteins with functional properties suitable for drug discovery applications. Operations center on advancing protein engineering techniques through computational methods, supporting research and development in therapeutics.
Profluent Bio's top competitors include Nimbus Therapeutics, Cradle and Eikon.
Profluent Bio offers OpenCRISPR and ProGen3.
Profluent Bio has 8 investors. Key investors include Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Phoenix Venture Partners.